Tehran (IP) - The second phase of the clinical trial of the Razi Cov-Pars COVID-19 vaccine kicked off on May 27 at Rasoul Akram Clinic in Tehran.

Iran PressIran news: "The promising results obtained from the first phase aiming to reassuring the vaccine's safety, having no serious side effects, and finding the right dose," an infectious disease specialist and the leading researcher of the 'COV-Pars COVID-19' project said.

Saeed Kalantari stated that in the first phase, the vaccine was injected in 3,5,10, and 20 doses, and based on the results obtained from the study, it seemed that 10-dose injection had the best results.

"In the 2nd phase, 500 volunteers in two groups of 250 got the jab. The first group has received a 10-dose, while the next group only received 'Adjuvant' (An adjuvant is a drug or other substance, or a combination of substances, use to increase the efficacy or potency of specific medications)," he noted.

"The vaccine's effectiveness depends on antibodies, and more or less than two months is needed to determine the outcome of the second phase, then the third phase will begin after ensuring that the vaccine is safe," he concluded.

207/203

Read more: 

Iran to import 7.5M doses of coronavirus vaccine

Non-Iranian nationals are being vaccinated in NE, Iran.